- Core One Labs’ (COOL) files patent for protection of its recombinant production system for optimized biosynthetic N-methyltryptamine (NMT)
- N-Methyltryptamine is a member of tryptamines and is an organic compound known to produce psychoactive effects
- The patent is entitled “Production of Psychedelic Compounds”
- The system is designed to make bacteria act as a biological factory and produce bioidentical psychedelic analogs
- A final patent approval would propel Core One past industry rivals since their game-changing production process enables mass-production of synthetic psilocybin
- Core One Labs’ (COOL) is down 13.46 per cent, trading at C$0.90 at 2:24 pm EST
Core One Labs’ (COOL) wholly-owned subsidiary, Vocan Biotechnologies, has filed a patent application with the United States Patent and Trademark Office.
This was done for the production of biosynthetic N-methyltryptamine through its optimized recombinant production system.
N-Methyltryptamine is a member of tryptamines and is an organic compound known to produce psychoactive effects when combined with a monoamine oxidase A inhibitor (MAOI).
The patent entitled “Production of Psychedelic Compounds” protects Core One’s novel proprietary production system.
The System, under the leadership of Dr. Jan Burian, Chief Scientist, and Dr. Robert EW Hancock, is designed to make bacteria act as a biological factory and produce bioidentical psychedelic analogs such as biosynthetic N-methyltryptamine (NMT).
Its production process can manufacture a more superior cGMP compliant API grade NMT than any chemically synthesized counterpart since it retains the stereochemistry of the natural psychedelic analogs found in hallucinogenic mushrooms.
Natural psilocybin and psychedelic-related molecules are known to have a more positive effect than those chemically synthesized; however, analog compounds can potentially be more effective and safer than natural compounds.
A final patent approval would propel Core One past industry rivals since their game-changing production process enables mass-production of synthetic psilocybin and other psychedelic compounds or analogs more rapidly, while also reducing the production cost and market price drastically.
It also maintains the quality and efficacy that are usually present in organically produced psychedelics.
“Filing this patent is an important milestone for the company since it allows us to protect our intellectual property against potential competitors,” stated Dr. Bob Hancock, CEO of Vocan Biotechnologies.
“The patent provides a broad array of strategies useful for making psychedelic compounds enabling Core One to diversify its product portfolio,” added Hancock.
Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy.
Core One Labs’ (COOL) is down 13.46 per cent, trading at C$0.90 at 2:24 pm EST.
